Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective (Q41073647)

26 September 2017

1 reference

title

Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective (English)

1 reference

26 September 2017

J E Tcheng

1

1 reference

26 September 2017

language of work or name

English

0 references

publication date

1 August 1996

1 reference

American Journal of Cardiology

26 September 2017

published in

1 reference

26 September 2017

volume

78

1 reference

26 September 2017

issue

3A

1 reference

26 September 2017

page(s)

35-40

1 reference

A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Integrins: a family of cell surface receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Activation affects access to the platelet receptor for adhesive glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(96)00490-0

10.1016/S0002-9149(96)00490-0

7 January 2021

Identifiers

DOI

1 reference

26 September 2017

1 reference